Crossmark

Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events

Crossref DOI link: https://doi.org/10.1007/s11886-018-0997-4

Published Online: 2018-05-25

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Sara

Cannon, Christopher P.
License Information

Text and Data Mining valid from 2018-05-25
More Information

Article History

First Online: 25 May 2018

Compliance with Ethical Standards

:

: Sara Lee declares that she has no conflict of interest.Christopher P. Cannon reports grants and personal fees from Arisaph, Boehringer Ingelheim, Takeda, Bristol-Myers Squibb, Amgen, and Merck; grants from Janssen and Daichi-Sankyo; and personal fees from GlaxoSmithKline, Lipimedix, Pfizer, Sanofi, Regeneron, Kowa, Alnylam, Amarin, Eisai, and AstraZeneca.

: This article does not contain any studies with human or animal subjects performed by any of the authors.